Zipper Urogynecology Specialist Educates Providers On New OAB Medicine

Fellowship-trained urogynecologist with Zipper Urogynecology, James Raders, MD, recently began a regional physician education campaign to introduce a new medicine for treatment of overactive bladder, known as Mybetriq™. Raders is among a small group of physicians nationwide who were tapped to teach healthcare providers about the drug, which received FDA approval earlier this year.

Myrbetriq, pronounced Meer-Bet-Rick, became available for women on the Space Coast in October. Unlike previous medicine-based treatments, Myrbetriq promotes bladder storage rather then fighting signals for bladder emptying. Mybetriq targets a specific receptor on the bladder, which relaxes the bladder muscle.

“OAB impacts each individual differently so it is important to have a variety of treatment options available,” said James Raders, MD. “Participating in the introduction of Myrbetriq is only one area where Zipper Urogyn is addressing the need to pursue more overactive bladder treatment options.”

Currently, Zipper Urogynecology is seeking participants for a research study for overactive bladder. The purpose of the research is to evaluate the effectiveness of investigational laser therapy in the treatment of overactive bladder in women. Eligible participants must be women over the age of 21, meet the American College of Obstetricians and Gynecologists (ACOG) definition of overactive bladder and urinary frequency and have failed to respond to non-invasive treatments for the underlying disorder or have declined other treatment.

Zipper Urogynecology Associates is the largest freestanding female pelvic medicine and reconstructive surgery practice in the United States. The practice accepts most major insurances including Medicare and Health First. The office is located at 1130 South Harbor City Blvd. in Melbourne, Florida. Contact them at 321.674.2114 or visit www.ZipperUrogyn.com.

 

Leave a comment

You must be logged in to post a comment.